Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Dual agonist at GLP-1 and GIP receptors
PMID: 7817664
The LEADER trial 28 (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) studied a 1.8-mg dose in more than 9,000 patients with type 2 diabetes and found the incidence of acute pancreatitis was similar between the liraglutide and placebo groups (0.4% vs 0.5%, respectively)
Beyond pancreatic and hepatic biology, tirzepatide is increasingly studied in central nervous system models
The profibrotic mechanism of ferroptosis is closely related to the TGF-/Smad pathway, and targeting ferroptosis and increasing GPX4 expression could be an effective strategy for treating CKD
By application, the type 2 diabetes mellitus segment led the global GLP-1 receptor agonist market in 2025
US$ 24.14
US$ 29.48
US$ 25.67
US$ 26.24
